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ABSTRACT 
 
Generic Drug Product approval is most stringent and crucial process for company with different rules and 
regulation in different country. For the registration of the product company has to follow regulatory rules 
and requirement of country specific agency. Company should apply product marketing authorization as per 
norms of country requirements and should manage life cycle of that product throughout market. Need to 
understand and describe the various regulatory requirements for the generic drug approval process and 
comparison of regulated country. To understand the technical requirements required to market medicines 
in regulated pharmaceutical market. To evaluate similarities and differences within regulated market of U.S, 
Canada, and Europe. To understand and evaluate differences of post approval Changes within regulated 
market. 
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INTRODUCTION 
Generic Drug is a pharmaceutical drug product iden-
tical, pharmaceutical equivalent and Bioequivalent or 
comparable to reference listed drug product in dos-
age form safety, strength, quality, performance char-
acteristics, and route of administration and intended 
use. An important factor for increasing demand of ge-
nerics drug is lower as well as decline price of prod-
uct which attract to customer. This generic drug 
product manufactures without notification or per-
mission of innovator Drug Company after expiration 
of patent and exclusivity right.[2] Using bioequiva-
lence as a tool to establish therapeutic equivalence 
between a reference and a generic product certainly 
forms the basis for market approval of multisource 
drug products as generic drug is a copy of branded 
drug. FDA detailed studied indicate that the generic 
drug request submitted to FDA for sanction must in-
clude the next: 
• The generic drug ‘pharmaceutical equivalent’ to 
the brand. 
• The ‘active Ingredient’ is the same as that of the 
brand. 
• The manufacturer is capable of making the drug 
in correct process. 
• The manufacturer is capable of making the drug 
consistently. 
• The right amount of the ingredient effect on that 
part of the body on the targeted area. 
• The ‘inactive ingredient’ of the drug is safe. 
• The container in which the drug will be shipped 
as well as sold is appropriate. 
• The label is the same as the brand-name drug’s 
label 
• Relevant patents or legal exclusivities are ex-
pired.[1] 
Patent Protection of Drug 
A company that developed a new drug product or 
drug substance should granted a patent for the drug 
itself, for usage for manufacturing and for method of 
administration and releasing the drug into blood 
stream. Hence a company must have more than one 
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patent for a drug. Patent provides company to exclu-
sive right of a drug for 20 years.[1] Usually about 10 
years pass between the drug is discovered (when the 
patent was filed) as well as the time of drug is ap-
proved for use, exit the company only about half of 
the patent life to the new drug. 
After a patent has expired, other company can sell as 
well as produce a generic version of a drug as the 
agency approved it. These generic drugs are sold at a 
lower price than the Branded drug the main reason is 
that the generic manufacture does not have to re-
cover the original cost of the drug development pro-
cess and hence not much spend on marketing of drug. 
A generic drug may be sold under its Brand name or 
its Generic name (A branded generic drug) but not 
under the brand name used by the original patent 
holder. 
Not all expired patent drugs have generic version. 
sometimes it’s very complex to duplicate or tests are 
not available to compare the generic drug acts simi-
larly as the branded drug. Eventually the market for 
the Drug is so small that producing another version is 
not profitable.[3] 
 
Figure 1: e-CTD Triangle 
Table 1: Regulation 
Regulation 
as per 
agencies 
US Canada Europe 
Agency Single Agency USFDA 
1. Health Canada 
2. Therapeutic Product Direc-
torate of Health Product Food 
Branch. (HPFB) 
Multiple Agencies 
1. EMEA (European Medical Eval-
uation Agency) 
2. National Health Agency 
Registration 
process 
Single Registration Process Single Registration Process 
Multiple Registration Process. 
1. Centralized Process: (European 
Community) 
2. Decentralized Process: (At 
least 2 Member State) 
3. Mutual Recognition Process: (At 
least 2 Member State) 
4. National (1Member State) 
Application 
Abbreviated New Drug Applica-
tion (ANDA) 
Abbreviated New Drug submis-
sion (ANDS) 
Marketing Authorization Applica-
tion (MAA) 
Stability 
data 
The Stability data for acceler-
ated Studies are submitted for 
3 Months at the time of original 
Submission 
The Stability data for accelerated 
Studies are submitted for com-
plete 6 Months at the time of orig-
inal Submission 
The Stability data for accelerated 
Studies are submitted for com-
plete 6 Months at the time of origi-
nal Submission 
Approval 
time 
18 Months 2 Years 12 Months 
Pharmaco-
peia 
US Pharmacopeia 
British Pharmacopeia, European 
Pharmacopeia, 
US Pharmacopeia 
British Pharmacopeia, European 
Pharmacopeia 
Table 2: Administration requirements 
Application Form 356 (h) HC/SC 3011 eAF Version 
1.23.1.0 
Agent Required Required Not Required 
Trend for previous 
submission non e-
CTD) 
Archival Copy – BLUE 
Review Copy –RED Field 
Copy– BURGENDY 
Module: 1- RED Module, 2-YELLOW Mod-
ule, 3- BLUE Module, 4- GREEN Module, 
5- BLACK 
Not Required 
Fees $178,799.00 $37,358.25 Different for different 
countries Application 
Paper size for sub-
mission 
Paper size (8.5 x 11) 
inches 11.69)inches 
Paper size (8.5 x 11) inches Paper size (8.27 x 
11.69) inches 
Font 12 (New Times Ro-
man) 
Font 12 (New Times Roman) Font 12 (New Times 
Roman) 
Table and Figures size 
i.e. 8-10 
Table and Figures size 
i.e. 9 
Table and Figures 
size 
i.e. 8-10 
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Dossier Format: e-CTD format 
• Module 1: Administrative information 
• Module 2: CTD Summaries 
• Module 3: Quality 
• Module 4: Nonclinical study reports 
• Module 5: Clinical study reports 
Outline of registration requirements of US, Canada 
Europe 
• Regulation 
• Administration requirements 
• Certifications 
• Raw material controls 
Table 3: Certifications 
Regulation 
as per agen-
cies 
US Canada Europe 
Environment 
assessment 
EAS (Environment Assess-
ment Statement) for cate-
gorical exclusion certificate 
in compliance with the law of 
EPA of US is Provided 
EAS is required for new Substances in 
product regulated under the F& D act 
as per the New Substances Notifica-
tion Regulations (NSN) of the Canadian 
Environmental Protection Act. 
(CEPA) 
Declaration for Environmental 
Risk Assessment is given with 
the Information from GMO or 
Non - GMO. The fresh/New Cer-
tificate is Provided 
Department 
Certificate 
Required Not Such Required Not Such Required 
Patent /ex-
clusivity 
statement 
Para I /II /III /IV Preferred Required 
Certificate of 
suitability 
It’s Not Applicable Preferred 
Certificate of Suitability to the 
monograph of the European 
Pharmacopeia (CEP) for the 
European Directorates for the 
Quality of Medicines (EDQM) 
VALIDITY: 5 years. 
Field copy 
certificate 
Required Not required for 
biological licensing applica-
tion (BLA) 
Not Such Required Not Such Required. 
Table 4: Raw material controls 
Regulation 
as per 
agencies 
US Canada Europe 
Definition of 
drug mas-
ter file 
A Drug Master File (DMF) is a Submission to the 
FDA. The main Objective is to Support regulatory 
requirement and to prove the quality, Safety, and 
efficacy. 
A DMF is a reference that 
provides information about 
specific process or compo-
nents used in the manufac-
turing processing and 
Packaging of a drug. 
In Europe drug Master 
File is Known as Ac-
tive Substance Master 
File (ASMF) or Euro-
pean Drug Master File 
(EDMF). 
Type of 
DMF 
Five Type of DMF: TYPE I: Manufacturing Site Fa-
cilities, Operating Procedure and Personnel, TYPE 
II: Drug Substance, Drug Substance Intermediate 
and Material Used in their Preparation, TYPE III: 
Packaging, TYPE IV: Excipient, Colorant, Flavor, 
Essence or Material used in their Preparation, 
TYPE V: FDA Acceptance Reference Information. 
Four Type of DMFs: 
TYPEI: Substance, Drug 
Intermediates and Materi-
als Used In their Prepara-
tion, TYPE II: Packaging 
Material, TYPE III: Color-
ants, Flavor and Other Ad-
ditives, TYPE IV: Dosage 
Form. 
Two Type of DMFs of: 
Drug Substances 
TYPE I : Applicant 
Part of DMF – Open 
Part.-(Non confiden-
tial), Type II: Re-
stricted Part of DMF -
Closed Part- (confi-
dential) 
Letter of 
Authoriza-
tion 
Required Required Required 
TSE/BSE 
TSE and BSE certificate are not attached in this 
section whereas Submitted in 
DMF. 
TSE and BSE certificate 
are not attached in this 
section whereas Submit-
ted in 
DMF. 
TSE and BSE certifi-
cate are not attached 
in this section 
whereas Submitted in 
DMF. 
Spectra 
Chromato-
gram 
Required No Such Requirement No Such Requirement 
Method 
Transfer 
Not Compulsory Compulsory Compulsory 
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• Composition 
• Manufacturing and controls 
• Finished product control requirements 
• Gmp requirements 
• Stability requirements 
• Labelling requirements 
• Bioequivalence requirements  
• Outside testing labs 
• Post-approval requirements 
Table 5: Composition 
Regulation as per agen-
cies 
US Canada Europe 
IIG database 
(Inactive ingredient) 
Must be within IIG Limit 
No such Database Re-
quired 
No such Database Re-
quired 
Iron content 
Maximum Daily Dose Should not be 
more 
than 5 mg / Day 
No such Requirement No such Requirement 
Table 6: Manufacturing and control 
Regulation as per agen-
cies 
US Canada Europe 
Batch size 
A minimum of 100,000 units 
OR 
10% of Total Commercial produc-
tion 
A minimum of 100,000 
units 
A minimum of 100,000 
units 
Packaging A minimum of 100,000 units No Such Requirements No Such Requirements 
Number of batches 
(validation batches) 
3 2 2 
Table 7: Finished product control requirements 
Regulation as per agencies US Canada Europe 
Justification ICH Q(6A) ICH Q(6A) ICH Q(6A) 
Assay 95 -105 % 95 -105 % 95 -105 % 
Colour Identification Not Required Not Required Required 
Water contents Required Required Not Required 
Table 8: GMP requirements 
Regulation as per 
agencies 
US Canada Europe 
Inspection FDA 
Health Product and 
Food Branch (HPFB) 
MHRA /PICS/EMA 
QP certification No required No required Required 
Clause 
21 CFR Part 210 
& 211 
Division 2, Part C of Food & Drug Regu-
lation of HPFB 
Volume 4,EU 
Guidelines of GMP for Medici-
nal Products 
Import distribution 
site 
No Such Re-
quired 
Required No Such Required 
Table 9: Stability requirements 
Regulation as per 
agencies 
US Canada Europe 
Number of batches 3 2 2 
Conditions 
(standard for room 
temperature storage) 
25°C 60 % RH 
30°C 65 % RH 
40°C 75 % RH 
25°C 60 % RH 
30°C 65 % RH 
40°C 75 % RH 
25°C 60 % RH 
30°C 65 % RH 
40°C 75 % RH 
Data at time of Sub-
mission 
6 months accelerated and 6 months 
long term 
6 months accelerated 
and 6 months long term 
6 months accelerated 
and 6 months long term 
Maximum shelf life 
24 Months and can be extend up to 
36 Months based on Stability data 
36 Months based on Sta-
bility data 
36 Months based on Sta-
bility data 
Container Orientation 
Invert &Upright / 
Horizontal 
Invert & Upright Invert & Upright 
Photo Stability 
 
Light Sensitive Products Light Sensitive Products Light Sensitive Products 
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Table 10: Labeling requirements 
Regulation 
as per agen-
cies 
US Canada Europe 
Number NDC (10 Digit) DIN (8 Digit) Not Required 
SPL/PLR Required Not Required Not Required 
Prescription 
Status 
Rx Pr, N POM 
Braille code Not Required Not Required Required 
Labels Vial/Cartons/PI 
Vial/Cartons/PI/Product Mono-
graph 
Vial/Cartons/PI/SPL 
Side by side 
comparison 
Annoted Draft Labeling (Side 
by Side) for label and carton 
compared with the RLD with 
Proper annotation is Provided 
Annoted Draft Labeling (Side by 
Side) for labels and carton com-
pared with the RLD with Proper 
annotation is Provided 
No Annotation (Side by Side) for 
labeling is Provided, Labeling and 
Package leaflet text as per inno-
vator to be Provided. 
Packaging 
Insert 
Packaging insert are provided 
for drug product in labeling 
Packaging insert are provided for 
drug product in labeling 
SPC (Summary of product char-
acterization) is provided about 
drug product in labeling 
Table 11: Generic drug label checkpoint of  
Difference 
Code 
US Canada Europe 
1 Company Name / Logo Company Name / Logo Company Name / Logo 
2 Braill Code Drug Identification Number Braill Code 
3 Generic name Generic name Generic name 
4 Rx/OTC Status Rx/OTC Status Rx/OTC Status 
5 Strength Strength Strength 
6 Pack size Pack size Pack size 
7 Name and Address Name and Address Name and Address 
8 Barcode Barcode Barcode 
9 Expiry Expiry Expiry 
10 Control/Lot No. Control/Lot No. Control/Lot No. 
11 Label Claim Label Claim Label Claim 
12 Storage instructions/Conditions Storage instructions/Conditions Storage instructions/Conditions 
13 Any other text/number Any other text/number Any other text/number 
14 - 2D Code - 
Table 12: Bioequivalence study 
Regulation as 
per agencies 
US Canada Europe 
CRO Audited by FDA Audited by FDA/Health Canada 
Audited by MHRA/EMEA 
(Medicine and Healthcare Product 
Regulatory Agency) 
Fasting/fed 
state studies 
Fasting or Fed/ both 
Depends on Product mono-
graph 
Fasting or Fed/ both 
Depends on Product monograph 
Fasting 
Analytical 
method valida-
tion parameters 
Accuracy, precision, selectiv-
ity, sensitivity, reproducibility, 
calibration curve, LOQ and 
stability 
Accuracy, precision, selectivity, 
sensitivity, reproducibility, cali-
bration curve, LOQ and stability 
Accuracy, precision, selectivity, 
sensitivity, reproducibility, calibra-
tion curve, LOQ and stability 
Study dose 
Made by the Manufacturer 
USA Reference listed drug in 
(Test Reference) 
Made by the manufacturer Ca-
nadian reference product (Test 
Reference) 
Made by the manufacturer Euro-
pean reference product. (Test 
Reference) 
Retention of 
samples 
5 years from the date of filing 
the application 
No such requirement, but usu-
ally followed 
No such requirement., but usually 
followed 
Sampling 
points 
12–18 samples, more 
Samples should be collected 
at Tmax 
At least 2 samples before ex-
pected Tmax, 
12–18 samples per subject/dose 
Study dose 
Made by the manufacturer 
reference listed drug in USA 
(Test Reference) 
Made by the manufacturer refer-
ence listed drug in Canada (Test 
Reference) 
Made by the manufacturer refer-
ence listed drug in Europe (Test 
Reference) 
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Figure 2: Generic Drug Label as per United States 
 
Figure 3: Generic drug label as per Canada 
 
Figure 4: Generic drug label as per Europe 
CONCLUSION 
World Pharmaceutical market is developing very fast 
but regulatory profile is different for various coun-
tries. The primary purpose of the rules governing me-
dicinal products in US, Canada, Europe is to safeguard 
public health. It is difficult to harmonize and switch 
the drug product from one country to another Regu-
latory rules divide world into two parts, one with reg-
ulated market like US, Japan, Europe, Australia, Can-
ada while other is semi regulated market such as 
LATAM Countries, ASEAN Countries, African Coun-
tries etc. This is due to the heterogeneity in the regu-
latory landscape of the various countries. United 
State is regulated country and it has a well-developed 
regulation. They developed new guidance for better 
safety and quality with using different approaches 
like QbD data integrity and vigilance monitoring FDA 
gives new guidance day by day. It is always tuff to ap-
proved product in US market. 
Canada is the 10th largest pharmaceutical market 
ranked in the world and second largest in North 
America. Continuous update in regulatory guidelines 
and rules makes the rules stuff and stringent for 
Pharma market to approved product in Canada mar-
ket. The Countries have different standards; there are 
high registration costs and long timelines for regis-
tration of generic drugs. This may account for the low 
market share of generics in Europe as compared to 
USA and Canada. 
This paper concluded specific requirements, tech-
nical Requirements, administration requirements 
and filling process and Bioequivalence Requirements, 
labeling requirements conclusion with using compar-
ative study in between United State, Canada and Eu-
rope. 
ABBREVIATIONS 
ANDA: Abbreviated New Drug Application, CEPA: Ca-
nadian Environment Protection Act, CFR: Code of 
Federal Regulation, c-GMP: Current Good Manufac-
turing Practices, DIN: Drug Identification Number, 
DMF: Drug Master File, e-CTD: Electronic – Common 
Technical Document, EMEA: European Commission 
and the European Medicines Agency, FDA: Food and 
Drug Administration, GCP: Good Clinical Practices, 
Table 13: Outside GMP labs 
Regulation as per agencies US Canada Europe 
GDEA Certificate Required Not Required Not Required 
c-GLP/c-GMP Certificate Required Not Required Not Required 
Contractual Agreement Not Required Not Required Required 
Table 14: Post approval changes  
Differ-
ence 
Code 
US Canada Europe 
Guide-
lines 
SUPAC (Scale up and Post Ap-
proval Changes) 
Supplements Variations 
Type 
Post-approval changes in the ap-
proved drug: 
1. Minor changes (CBE 0) 
2. Moderate changes (CBE 30) 
3. Major changes (Prior Approval 
Changes) 
Post-approval changes in the 
approved drug: 
1. Minor changes 
2. Moderate changes 
3. Major changes 
Post-variation in the approved drug: 
1. Type IA Variation (Do and tell) 
2. Type IB Variation (Tell- Wait and 
Do Procedure) 
3.  Type II Variation (Major 
Changes) 
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GLP: Good Laboratory Practices, GMP: Good Manufac-
turing Practices, PAS: Prior Approval Changes, QP: 
Quality of Product, RTR: Refuse to Receive, USFDA: 
United State Food and Drug Administration, USA: 
United State of America, WHO: World Health Organi-
zation. 
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